GUSELKUMAB INDUCTION RESTORES INTESTINAL IMMUNE HOMEOSTASIS AND PROMOTES EPITHELIAL REPAIR IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

被引：0
|
作者：
Sridhar, Sunan
Hart, Amy
Venkat, Swati
Ruane, Darren
Horowitz, Dan
Lee, Tae
Waterworth, Dawn M.
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Vetter, Marion
Cua, Daniel
Freeman, Tom C.
Sisk, Christopher
Mcrae, Bradford
Verstockt, Bram
Rubin, David T.
Sands, Bruce E.
Branigan, Patrick
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1732
引用
收藏
页码：S790 / S790
页数：1
相关论文
共 50 条
  • [41] A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis
    Law, Cindy C. Y.
    Kayal, Maia
    Mehandru, Saurabh
    Colombel, Jean-Frederic
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2023, 17 (02) : 109 - 117
  • [42] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Yasuo Suzuki
    Satoshi Motoya
    Hiroyuki Hanai
    Takayuki Matsumoto
    Toshifumi Hibi
    Anne M. Robinson
    Nael M. Mostafa
    Jingdong Chao
    Vipin Arora
    Anne Camez
    Roopal B. Thakkar
    Mamoru Watanabe
    Journal of Gastroenterology, 2014, 49 : 283 - 294
  • [43] A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis
    Aoun, Roni
    Hanauer, Stephen
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (05) : 411 - 423
  • [44] Integrated summary of safety of obefazimod for patients with moderately to severely active ulcerative colitis
    Vermeire, S.
    Peyrin-Biroulet, L.
    Danese, S.
    Dubinsky, M.
    Dulai, P. S.
    Tilg, H.
    Siegmund, B.
    Hisamatsu, T.
    Shan, K.
    Jacobstein, D.
    Cataldi, F.
    Rabbat, C.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1554 - i1555
  • [45] Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
    Suzuki, Yasuo
    Motoya, Satoshi
    Hanai, Hiroyuki
    Matsumoto, Takayuki
    Hibi, Toshifumi
    Robinson, Anne M.
    Mostafa, Nael M.
    Chao, Jingdong
    Arora, Vipin
    Camez, Anne
    Thakkar, Roopal B.
    Watanabe, Mamoru
    JOURNAL OF GASTROENTEROLOGY, 2014, 49 (02) : 283 - 294
  • [46] Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis
    Ernest-Suarez, Kenneth
    Panaccione, Remo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [47] The Effect of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results at Week 12 by Prior Inadequate Response or Intolerance to Advanced
    Rubin, David T.
    Allegretti, Jessica R.
    Sands, Bruce E.
    Huang, Kuan-Hsiang
    Kavalam, Mary
    Germinaro, Matthew
    Wilson, Rebbecca
    Zhang, Hongyan
    Mihaly, Emese
    Hisamatsu, Tadakazu
    Dignass, Axel
    Panes, Julian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S500 - S501
  • [48] GUSELKUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY PROMIS-29 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR INDUCTION STUDY
    Panes, Julian
    Dignass, Axel
    Lichtenstein, Gary R.
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Houck, Nicole
    Han, Chenglong
    Miao, Ye
    Zhang, Hongyan
    Abu Farsakh, Niazy A.
    Patel, Bhaktasharan
    Owczarek, Danuta
    Hisamatsu, Tadakazu
    Sands, Bruce E.
    Bressler, Brian
    GASTROENTEROLOGY, 2024, 166 (05) : S848 - S848
  • [49] Guselkumab improves health-related quality of life as measured by PROMIS-29 in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study
    Panes, J.
    Dignass, A.
    Lichtenstein, G.
    Huang, K. H.
    Germinaro, M.
    Houck, N.
    Han, C.
    Miao, Y.
    Zhang, H.
    Abu Farsakh, N.
    Patel, B.
    Owczarek, D.
    Hisamatsu, T.
    Sands, B.
    Bressler, B.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I160 - I161
  • [50] Improvement in Inflammatory Biomarker Levels Through Week 12 in Moderately to Severely Active Ulcerative Colitis Patients Treated With Guselkumab: Results From the Phase 3 QUASAR Induction Study
    Hisamatsu, Tadakazu
    Peyrin-Biroulet, Laurent
    Dignass, Axel
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Houck, Nicole
    Miao, Ye
    Zhang, Hongyan
    Argollo, Marjorie
    Takeuchi, Ken
    Filip, Rafal
    Allegretti, Jessica R.
    Feagan, Brian G.
    Sands, Bruce E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S810 - S810
12345